| # | Title | Journal | Year | Citations |
|---|
| 1 | Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines | Journal of Extracellular Vesicles | 2018 | 6,961 |
| 2 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Lancet Oncology, The | 2009 | 5,104 |
| 3 | Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel | Blood | 2017 | 4,375 |
| 4 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges | International Journal of Antimicrobial Agents | 2020 | 4,124 |
| 5 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Lancet, The | 2018 | 3,542 |
| 6 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Lancet, The | 2017 | 3,224 |
| 7 | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 2,771 |
| 8 | Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update | Hepatology International | 2016 | 1,908 |
| 9 | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial | Lancet Oncology, The | 2018 | 1,816 |
| 10 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study | Lancet, The | 2019 | 1,804 |
| 11 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 1,749 |
| 12 | Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children | New England Journal of Medicine | 1997 | 1,724 |
| 13 | Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer | New England Journal of Medicine | 2019 | 1,582 |
| 14 | MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Proceedings of the National Academy of Sciences of the United States of America | 2007 | 1,557 |
| 15 | Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update | Hepatology International | 2017 | 1,537 |
| 16 | Fate Tracing Reveals the Pericyte and Not Epithelial Origin of Myofibroblasts in Kidney Fibrosis | American Journal of Pathology | 2010 | 1,281 |
| 17 | B cells are associated with survival and immunotherapy response in sarcoma | Nature | 2020 | 1,158 |
| 18 | Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial | Lancet, The | 2007 | 1,153 |
| 19 | Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 | JAMA - Journal of the American Medical Association | 2020 | 1,032 |
| 20 | Ambient Particulate Air Pollution and Daily Mortality in 652 Cities | New England Journal of Medicine | 2019 | 978 |
| 21 | Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis | Lancet, The | 2008 | 976 |
| 22 | Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility | Nature Genetics | 2014 | 959 |
| 23 | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial | Lancet Oncology, The | 2016 | 943 |
| 24 | Mapping genomic loci implicates genes and synaptic biology in schizophrenia | Nature | 2022 | 929 |
| 25 | First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study | Lancet, The | 2017 | 919 |
| 26 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 | Annals of Oncology | 2017 | 844 |
| 27 | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update | Hepatology International | 2008 | 832 |
| 28 | International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data | Blood | 2022 | 814 |
| 29 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN | Blood | 2022 | 805 |
| 30 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | Lancet Oncology, The | 2019 | 767 |
| 31 | Generalized ${ q}$-Sampling Imaging | IEEE Transactions on Medical Imaging | 2010 | 760 |
| 32 | MicroRNA Signature Predicts Survival and Relapse in Lung Cancer | Cancer Cell | 2008 | 754 |
| 33 | VPS35 Mutations in Parkinson Disease | American Journal of Human Genetics | 2011 | 747 |
| 34 | Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib | JAMA Oncology | 2020 | 746 |
| 35 | Ulcerative colitis | Nature Reviews Disease Primers | 2020 | 678 |
| 36 | Infections in the survivors of out-of-hospital cardiac arrest in the first 7 days | Intensive Care Medicine | 2005 | 661 |
| 37 | Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis | Journal of Thoracic Oncology | 2017 | 653 |
| 38 | Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial | Lancet Oncology, The | 2018 | 648 |
| 39 | Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan | New England Journal of Medicine | 2011 | 631 |
| 40 | Loneliness and social isolation during the COVID-19 pandemic | International Psychogeriatrics | 2020 | 625 |
| 41 | Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer | Journal of Clinical Oncology | 2020 | 614 |
| 42 | A Novel Virulence Gene in Klebsiella pneumoniae Strains Causing Primary Liver Abscess and Septic Metastatic Complications | Journal of Experimental Medicine | 2004 | 609 |
| 43 | Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression | Cancer Research | 2007 | 605 |
| 44 | Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study | Lancet Oncology, The | 2018 | 587 |
| 45 | Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2015 | 574 |
| 46 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma | Journal of Hepatology | 2022 | 568 |
| 47 | Environmental risk factors and Parkinson's disease | Neurology | 1997 | 565 |
| 48 | Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity | Clinical Cancer Research | 2016 | 554 |
| 49 | Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians | Nature Genetics | 2012 | 545 |
| 50 | Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study | Journal of the National Cancer Institute | 2009 | 534 |
